To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy
- PMID: 24799991
- PMCID: PMC4009478
- DOI: 10.4254/wjh.v6.i4.226
To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy
Abstract
Hepatitis B virus (HBV) infection is a global public health problem, with an estimated 350 million people worldwide chronically infected and approximately 500000 who die annually from HBV-related liver diseases. Management of chronic HBV is challenging and waves of guidelines emerge every year. One of the hottest topics and a matter of debate is the management of patients in their early immunotolerant phase of infection. With the lack of evidence, dealing with this particular subset of patients creates a great conflict with opposing views. In this review, the author highlights the pros and cons of these views and proposes a reasonable solution to resolve this dilemma.
Keywords: Hepatitis B Virus; Immunotolerant phase; Liver biopsy; Nucleotide analogue; Polymerase chain reaction.
References
-
- Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. - PubMed
-
- Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–1956. - PubMed
-
- Daniels G. A century of human blood groups. Wien Klin Wochenschr. 2001;113:781–786. - PubMed
-
- Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
